Title |
Evolution to plasmablastic lymphoma evades CD19‐directed chimeric antigen receptor T cells
|
---|---|
Published in |
British Journal of Haematology, June 2015
|
DOI | 10.1111/bjh.13562 |
Pubmed ID | |
Authors |
Andrew G Evans, Paul G Rothberg, W Richard Burack, Scott F Huntington, David L Porter, Jonathan W Friedberg, Jane L Liesveld |
Abstract |
A patient with relapsed and refractory chronic lymphocytic leukaemia with Richter transformation was treated with chimeric antigen receptor (CAR)-modified T cells targeted for CD19 but later relapsed with a clonally related plasmablastic lymphoma. The loss of most routine markers of pre-plasma cell or B lymphoid differentiation (including CD19) highlights the ability of such mature lymphomas to evade lineage-specific targeted immunotherapy by differentiating along pathways comparable to their normal cellular counterparts. Molecular genetic evaluation demonstrated multiple independent lines of CD19-negative disease that eventually evolved in this single patient. Such plasticity represents potential challenges for antigen-directed CAR-T cell therapy, while serving as a testament to the selective pressure exerted by these engineered T cells over time. |
X Demographics
Geographical breakdown
Country | Count | As % |
---|---|---|
Japan | 2 | 67% |
Unknown | 1 | 33% |
Demographic breakdown
Type | Count | As % |
---|---|---|
Members of the public | 3 | 100% |
Mendeley readers
Geographical breakdown
Country | Count | As % |
---|---|---|
Unknown | 74 | 100% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Researcher | 14 | 19% |
Student > Ph. D. Student | 13 | 18% |
Student > Master | 12 | 16% |
Student > Bachelor | 5 | 7% |
Other | 5 | 7% |
Other | 6 | 8% |
Unknown | 19 | 26% |
Readers by discipline | Count | As % |
---|---|---|
Medicine and Dentistry | 27 | 36% |
Agricultural and Biological Sciences | 8 | 11% |
Immunology and Microbiology | 8 | 11% |
Biochemistry, Genetics and Molecular Biology | 6 | 8% |
Pharmacology, Toxicology and Pharmaceutical Science | 4 | 5% |
Other | 3 | 4% |
Unknown | 18 | 24% |